We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Nonradioactive Serotonin Release Assay Compared to Gold Standard

By LabMedica International staff writers
Posted on 01 Feb 2016
Print article
The JANUS Automated Liquid Handling Workstation
The JANUS Automated Liquid Handling Workstation (Photo courtesy of Perkin Elmer)
The serotonin release assay (SRA) is considered the gold standard laboratory test for heparin-induced thrombocytopenia (HIT) and the classical SRA method uses platelets loaded with radiolabeled serotonin to evaluate platelet activation by HIT immune complexes.

Laboratory tests for HIT consist of immunoassays, usually enzyme-linked immunosorbent assays (ELISAs), and functional platelet activation assays. Immunoassays detect the presence of immunoglobulins that bind heparin: PF4 complexes, while functional tests detect platelet activation by immune complexes consisting of macromolecular aggregates of heparin: PF4 and antibody.

Scientists at the ARUP Laboratories Institute (Salt Lake City, UT, USA) and their colleagues have validated the performance characteristics of a high-performance liquid chromatography (HPLC) SRA method. The team used serum samples stored frozen until the time of evaluation that had been submitted to their laboratory for HIT testing. Reagent platelets were obtained by collecting blood from healthy donors known to be reactive and with no history of HIT, platelet dysfunction, or current nonsteroidal anti-inflammatory drugs (NSAID) use.

Assay setup was automated on a JANUS liquid handling system (PerkinElmer, Waltham, MA, USA), although platelets were pipetted manually. Serotonin released from reagent platelets was quantitated (ng/mL) by HPLC on a gel permeation chromatography (GPC), size exclusion chromatography (SEC), 1260 instrument (Agilent Technologies; Santa Clara, CA, USA) with fluorescent detection (excitation 285 nm, emission 345 nm). Results were expressed as percentage release and classified as positive, negative, or indeterminate based on previously published cutoffs.

The serum samples from 250 subjects with suspected HIT were tested in the HPLC-SRA and with the radioactive method. Concordant classifications were observed in 230 samples (92%). Sera from 41 healthy individuals tested negative. Between-run imprecision studies showed standard deviation of less than 6% release for positive, weak positive and negative serum pools. Stability studies demonstrated stability after two freeze–thaw cycles or up to a week of refrigeration.

The authors concluded that the HPLC-SRA has robust performance characteristics, equivalent to the classic radioactive method, which has long been considered the gold standard assay for HIT. Results from nonradioactive SRA methods using novel serotonin detection methods provide equivalent information to radioactive methods for HIT diagnostic algorithms but avoid the laboratory complexities of working with radioactivity. The HPLC-SRA method has been optimized to accommodate the demands placed on our high-volume reference laboratory by use of an automated dilutor to perform many pipetting steps and laboratory-developed software to perform calculations. The study was published in the February 2016 issue of the International Journal of Laboratory Hematology.

Related Links:

ARUP Laboratories Institute 
Perkin Elmer 
Agilent Technologies 


New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Calprotectin Assay
Fecal Calprotectin ELISA
New
Silver Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.